share_log

华海药业(600521.SH)子公司长兴制药2023年度净利润6691.74万元 同比增长10.74%

Changxing Pharmaceutical, a subsidiary of Huahai Pharmaceutical (600521.SH), increased 10.74% year-on-year in 2023 net profit of 669.17,400 yuan

Zhitong Finance ·  Mar 18 05:10

Huahai Pharmaceutical (600521.SH) issued an announcement stating that the company's holding subsidiary Changxing Pharmaceutical Co., Ltd. (abbreviation “...

Zhitong Finance App News, Huahai Pharmaceutical (600521.SH) announced that the company's holding subsidiary Changxing Pharmaceutical Co., Ltd. (“Changxing Pharmaceutical”, stock code “835269”) is a listed company at the innovation level of the national SME share transfer system. Changxing Pharmaceutical disclosed the “2023 Annual Report of Changxing Pharmaceutical Co., Ltd.” on the National SME Share Transfer System on March 18, 2024.

During the reporting period, Changxing Pharmaceutical achieved operating income of 468 million yuan, a year-on-year increase of 45.82%; net profit attributable to shareholders of the parent company was 669.17,400 yuan, up 10.74% year on year; net profit attributable to shareholders of the parent company after deducting non-recurring profit and loss was 62.9761 million yuan, an increase of 13.19% year on year; basic earnings per share were 1.12 yuan/share.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment